Implementation perspective demonstrates scalable adoption of a material–process–workflow framework across medical photopolymer pipelines, indicating high industrial reproducibility.
The Material–Process–Workflow framework developed in the first paper of this trilogy proposes that device-level biological performance in photopolymer additive manufacturing is determined by the coupled interaction of material chemistry, cure kinetics and post-processing workflow rather than by chemistry alone. The remaining engineering question is whether such a framework operates reproducibly under industrial production conditions. This second perspective applies the framework to two production-scale implementation cases. The first case is the H3D custom hearing-device manufacturing pipeline, which integrates iPhone TrueDepth scanning, statistical 3D modelling, direct photopolymer additive manufacturing, validated post-processing and ISO 13485 release. The implementation exceeds one million cumulative custom devices since 2019 and operates at a current automation level above 100,000 designs per month. Independent process-window characterisation conducted at the Technical University of Denmark supports the cure-kinetics component of the implementation. The second case applies the framework to a commercial monomer-free dental photopolymer architecture spanning continuous-contact (direct-printed aligners), intermittent-contact (denture bases and occlusal splints) and semi-permanent (interim crown and bridge) applications. Across both cases the framework supports sustained operational implementation at industrial scale, with the cure-kinetics and post-processing workflow components documented through manufacturer technical data and independent peer-reviewed process characterisation where available. The cases are presented as industrial-academic implementation perspectives rather than as controlled clinical validation studies. Cross-vendor extractables benchmarking and longer-term clinical outcome studies remain necessary to establish generalised biological performance claims.
No takes yet. Share an insight, caveat, or question.
Juan Segurola (2026) studied this question.
Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context: